These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Decreased insulin secretion in patients receiving tacrolimus as GVHD prophylaxis after allogeneic hematopoietic SCT. Fuji S; Kim SW; Mori S; Furuta K; Tanosaki R; Heike Y; Takaue Y; Fukuda T Bone Marrow Transplant; 2010 Feb; 45(2):405-6. PubMed ID: 19648969 [No Abstract] [Full Text] [Related]
10. [Usefulness of a slow-release tacrolimus for a patient with tacrolimus-induced renal injury after hemopoietic stem cell transplantation]. Hosonuma R; Fujiwara S; Sasazaki M; Hirata Y; Yamamoto C; Uesawa M; Oh I; Matsuyama T; Mori M; Ozawa K; Muroi K Rinsho Ketsueki; 2012 Apr; 53(4):469-71. PubMed ID: 22687983 [TBL] [Abstract][Full Text] [Related]
11. Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases. Miyakoshi S; Kami M; Tanimoto T; Yamaguchi T; Narimatsu H; Kusumi E; Matsumura T; Takagi S; Kato D; Kishi Y; Murashige N; Yuji K; Uchida N; Masuoka K; Wake A; Taniguchi S Transplantation; 2007 Aug; 84(3):316-22. PubMed ID: 17700155 [TBL] [Abstract][Full Text] [Related]
12. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. Saberian C; Abdel-Wahab N; Abudayyeh A; Rafei H; Joseph J; Rondon G; Whited L; Gruschkus S; Fa'ak F; Daher M; Knape C; Safa H; Shoukier M; Suarez-Almazor ME; Marcotulli M; Ludford K; Gulbis AM; Konopleva M; Ohanian M; Ravandi F; Garcia-Manero G; Oran B; Popat UR; Mehta R; Alousi AM; Daver N; Champlin R; Diab A; Al-Atrash G J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637601 [TBL] [Abstract][Full Text] [Related]
13. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Rodriguez R; Nakamura R; Palmer JM; Parker P; Shayani S; Nademanee A; Snyder D; Pullarkat V; Kogut N; Rosenthal J; Smith E; Karanes C; O'Donnell M; Krishnan AY; Senitzer D; Forman SJ Blood; 2010 Feb; 115(5):1098-105. PubMed ID: 19965688 [TBL] [Abstract][Full Text] [Related]
14. Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid-resistant acute graft-versus-host disease developing during cyclosporine prophylaxis. Mollee P; Morton AJ; Irving I; Durrant S Br J Haematol; 2001 Apr; 113(1):217-23. PubMed ID: 11328304 [TBL] [Abstract][Full Text] [Related]
15. Practical considerations in the use of tacrolimus for allogeneic marrow transplantation. Przepiorka D; Devine S; Fay J; Uberti J; Wingard J Bone Marrow Transplant; 1999 Nov; 24(10):1053-6. PubMed ID: 10578154 [TBL] [Abstract][Full Text] [Related]
16. [Case of encephalopathy seemingly caused by tacrolimus at blood concentration near the upper limit of therapeutic range]. Yamaguchi K; Fukuoka N; Kimura S; Shinohara N; Tatsumichi T; Tai T; Kosaka S; Ohnishi H; Houchi H Yakugaku Zasshi; 2012; 132(7):845-8. PubMed ID: 22790031 [TBL] [Abstract][Full Text] [Related]
17. Eye Movement Disorders Following Allogeneic Bone Marrow Transplantation on FK506 (Tacrolimus) and Ganciclovir. Karagun BS; Akbas T; Arpaci T; Antmen B J Pediatr Hematol Oncol; 2018 Jan; 40(1):71-73. PubMed ID: 28731920 [TBL] [Abstract][Full Text] [Related]
18. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Przepiorka D; Ippoliti C; Khouri I; Woo M; Mehra R; Le Bherz D; Giralt S; Gajewski J; Fischer H; Fritsche H; Deisseroth AB; Cleary K; Champlin R; Besien K; Andersson B; Maher R; Fitzsimmons W Blood; 1996 Dec; 88(11):4383-9. PubMed ID: 8943876 [TBL] [Abstract][Full Text] [Related]
19. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis. Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738 [TBL] [Abstract][Full Text] [Related]
20. Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis. Snyder DS; Palmer J; Gaal K; Stein AS; Pullarkat V; Sahebi F; Vora N; Nakamura R; Forman SJ Biol Blood Marrow Transplant; 2010 Feb; 16(2):281-6. PubMed ID: 19786111 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]